Pharmacologic interventions aimed at preventing the biologic effects of endotoxin.
In summary, an increased understanding of the pathogenesis and pathophysiology of septic shock has led to the development and evaluation of potential adjunctive therapies. Although several agents show promise in certain experimental settings, definitive recommendations regarding the use of these agents are not yet possible. Although several therapies have shown benefit when the subject receives treatment prior to the onset of sepsis, most have had varying degrees of success following the development of septicemia.
Sable
C A
CA
Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville.
Wispelwey
B
B
D000818:Animals; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004731:Endotoxins / Q000037:antagonists & inhibitors*; D006090:Gram-Negative Bacteria / Q000378:metabolism; D016905:Gram-Negative Bacterial Infections / Q000378:metabolism / Q000517:prevention & control*; D006801:Humans; D009270:Naloxone / Q000494:pharmacology*; D010431:Pentoxifylline / Q000494:pharmacology*; D012772:Shock, Septic / Q000378:metabolism / Q000517:prevention & control
D016861:Cyclooxygenase Inhibitors; D004731:Endotoxins; D009270:Naloxone; D010431:Pentoxifylline